{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:27:22Z","timestamp":1790458042695,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jconrel.2018.07.013","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T23:01:40Z","timestamp":1533078100000},"page":"244-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Non-viral ocular gene therapy, pEYS606, for the treatment of non-infectious uveitis: Preclinical evaluation of the medicinal product"],"prefix":"10.1016","volume":"285","author":[{"given":"Elodie","family":"Touchard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Benard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Bigot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Denis","family":"Laffitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Buggage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Bordet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Behar-Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2018.07.013_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative","author":"Dick","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2018.07.013_bb0010","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2018.07.013_bb0015","first-page":"5397","article-title":"Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis","volume":"9","author":"Ba","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0020","article-title":"Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia","volume":"12","author":"Zhu","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0025","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ophtha.2014.10.013","article-title":"Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology","volume":"122","author":"Yeh","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2018.07.013_bb0030","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis","volume":"6","author":"Virgili","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0035","article-title":"Predictors of one-year visual outcomes after anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration","author":"Kodjikian","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.jconrel.2018.07.013_bb0040","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","article-title":"Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases","volume":"255","author":"Lanzetta","year":"2017","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0045","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.preteyeres.2010.04.001","article-title":"Protein delivery for retinal diseases: from basic considerations to clinical applications","volume":"29","author":"El Sanharawi","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0050","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14728214.2017.1362390","article-title":"Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration","volume":"22","author":"Hussain","year":"2017","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.jconrel.2018.07.013_bb0055","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2018.07.013_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.joco.2018.01.006","article-title":"Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation","volume":"30","author":"Ameri","year":"2018","journal-title":"J. Curr. Ophthalmol."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0065","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1167\/iovs.02-1063","article-title":"The role of advanced glycation end products in retinal microvascular leukostasis","volume":"44","author":"Moore","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0070","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2174\/1566523217666171116170040","article-title":"The role of gene therapy in the treatment of retinal diseases: a review","volume":"17","author":"Campa","year":"2017","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev-vision-102016-061413","article-title":"Vectors and gene delivery to the retina","volume":"3","author":"Planul","year":"2017","journal-title":"Annu. Rev. Vis. Sci."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0080","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000479157","article-title":"Subretinal injection: a review on the novel route of therapeutic delivery for vitreoretinal diseases","volume":"58","author":"Peng","year":"2017","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0085","first-page":"389","article-title":"Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF-alpha soluble receptor in uveitis","volume":"20","author":"Bloquel","year":"2006","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0090","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.addr.2006.07.023","article-title":"Non-viral ocular gene therapy: potential ocular therapeutic avenues","volume":"58","author":"Bloquel","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0095","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.survophthal.2006.12.005","article-title":"Electrically assisted ocular gene therapy","volume":"52","author":"Bejjani","year":"2007","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0100","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/gt.2009.43","article-title":"Effects of ciliary muscle plasmid electrotransfer of TNF-alpha soluble receptor variants in experimental uveitis","volume":"16","author":"Touchard","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0105","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/jgm.1517","article-title":"The ciliary smooth muscle electrotransfer: basic principles and potential for sustained intraocular production of therapeutic proteins","volume":"12","author":"Touchard","year":"2010","journal-title":"J. Gene Med."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0110","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1167\/iovs.08-3027","article-title":"Local ocular immunomodulation resulting from electrotransfer of plasmid encoding soluble TNF receptors in the ciliary muscle","volume":"50","author":"Kowalczuk","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12033-010-9310-5","article-title":"Vector insert-targeted integrative antisense expression system for plasmid stabilization","volume":"47","author":"Luke","year":"2011","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0120","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.clim.2009.01.002","article-title":"Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor","volume":"131","author":"Kaymakcalan","year":"2009","journal-title":"Clin. Immunol. Orlando Fla"},{"key":"10.1016\/j.jconrel.2018.07.013_bb0125","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1084\/jem.174.6.1483","article-title":"A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity","volume":"174","author":"Peppel","year":"1991","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0130","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1006\/jaut.1998.0197","article-title":"Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis","volume":"11","author":"Dick","year":"1998","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/eye.2016.177","article-title":"Doyne lecture 2016: intraocular health and the many faces of inflammation","volume":"31","author":"Dick","year":"2017","journal-title":"Eye"},{"key":"10.1016\/j.jconrel.2018.07.013_bb0140","first-page":"135","article-title":"Adalimumab: a review in Non-infectious non-anterior uveitis","volume":"31","author":"Hoy","year":"2017","journal-title":"BioDrugs Clin. Immunother. Biopharm. Gene Ther."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.31407","article-title":"Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions","author":"Calip","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2018.07.013_bb0150","doi-asserted-by":"crossref","DOI":"10.1111\/aos.13699","article-title":"Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review","author":"Leal","year":"2018","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0155","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3389\/fimmu.2018.00444","article-title":"Tumor Necrosis Factor \u03b1 and Regulatory T Cells in Oncoimmunology","volume":"9","author":"Salomon","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2018.07.013_bb0160","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/gt.2011.154","article-title":"Non-viral gene therapy for GDNF production in RCS rat: the crucial role of the plasmid dose","volume":"19","author":"Touchard","year":"2012","journal-title":"Gene Ther."},{"issue":"4","key":"10.1016\/j.jconrel.2018.07.013_bb0165","first-page":"625","article-title":"Intranasal administration of retinal antigens suppresses retinal antigen-induced experimental autoimmune uveoretinitis","volume":"82","author":"Dick","year":"1994","journal-title":"Immunology"},{"issue":"11","key":"10.1016\/j.jconrel.2018.07.013_bb0170","doi-asserted-by":"crossref","first-page":"e49036","DOI":"10.1371\/journal.pone.0049036","article-title":"The aldosterone-mineralocorticoid receptor pathway exerts anti-inflammatory effects in endotoxin-induced uveitis","volume":"7","author":"Bousquet","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jconrel.2018.07.013_bb0175","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.03-0659","article-title":"Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation","volume":"45","author":"Greiner","year":"2004","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"12","key":"10.1016\/j.jconrel.2018.07.013_bb0180","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1002\/eji.200425022","article-title":"Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis","volume":"34","author":"de Kozak","year":"2004","journal-title":"Eur J Immunol"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918304073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918304073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:38:02Z","timestamp":1759160282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365918304073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":36,"alternative-id":["S0168365918304073"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.07.013","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-viral ocular gene therapy, pEYS606, for the treatment of non-infectious uveitis: Preclinical evaluation of the medicinal product","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}